Estimation of the Number of Individuals Living With Metastatic Cancer in the United States

Author:

Gallicchio Lisa1ORCID,Devasia Theresa P1,Tonorezos Emily1ORCID,Mollica Michelle A1,Mariotto Angela1

Affiliation:

1. Division of Cancer Control and Population Sciences, National Cancer Institute , Rockville, MD, USA

Abstract

Abstract Background The purpose of this study was to estimate the number of individuals living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma in the United States using population-based data. Methods A back-calculation method was used to estimate the number of individuals living with metastatic cancer for each cancer type from US cancer mortality and survival statistics from the Surveillance, Epidemiology, and End Results registries. The percentages of those living with metastatic cancer who advanced to metastatic disease from early stage cancer vs who were diagnosed with metastatic cancer de novo were calculated. One- and 5-year relative survival rates for de novo metastatic cancer were compared by year of diagnosis to assess time trends in survival. Results It is estimated that, in 2018, 623 405 individuals were living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in the United States. This number is expected to increase to 693 452 in 2025. In 2018, the percentage of metastatic cancer survivors who were initially diagnosed with early stage cancer and advanced to metastatic cancer ranged from 30% for lung cancer to 72% for bladder cancer. Conclusions This study demonstrates increasing numbers of individuals living with metastatic cancer of the 6 most common cancer types in the United States. This information is critical for informing the allocation of research efforts and healthcare infrastructure needed to address the needs of these individuals.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference14 articles.

1. Cancer treatment and survivorship statistics, 2019;Miller;CA A Cancer J Clin,2019

2. Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute meeting report;Mollica;J Natl Cancer Inst,2021

3. Estimation of the number of women living with metastatic breast cancer in the United States;Mariotto;Cancer Epidemiol Biomarkers Prev,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3